Altamira Therapeutics Ltd's Comment on Sales, Marketing and Customers
The company operates within the biopharmaceutical industry, focusing on treatments for KRAS-driven cancers and rheumatoid arthritis (RA). In the KRAS-driven cancer segment, the market includes companies such as Amgen and Mirati Therapeutics, which have FDA-approved KRAS G12C inhibitors sotorasib and adagrasib for non-small cell lung cancer (NSCLC) with G12C-mutated KRAS. Additional companies developing treatments targeting single KRAS mutations include Genentech, Eli Lilly, Revolution Medicine, Boehringer Ingelheim, Silexion Therapeutics, and Nitto Denko. Treatments addressing multiple KRAS mutations are under development by Revolution Medicines, Boehringer Ingelheim, Eli Lilly, and Alterome Therapeutics.
In the rheumatoid arthritis market, competition involves large pharmaceutical companies marketing biologics targeting tumor necrosis factor-alpha (TNF-α), including adalimumab (AbbVie), infliximab (Johnson & Johnson), and etanercept (Amgen). Other biologics target B cells (rituximab, Roche), T cells (abatacept, Bristol-Myers Squibb), and interleukin-6 (tocilizumab, Genentech). Biosimilars have been introduced following patent expirations. Small molecule Janus kinase (JAK) inhibitors marketed by major companies include upadacitinib (AbbVie), tofacitinib (Pfizer), and baricitinib (Eli Lilly). Older therapies such as glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and disease-modifying antirheumatic drugs (DMARDs) also remain part of the RA treatment landscape.
Key customers and market participants identified include AbbVie, Alterome Therapeutics, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Genentech, Johnson & Johnson, Mirati Therapeutics, Nitto Denko, Pfizer, Revolution Medicine, Roche, and Silexion Therapeutics.
In an exciting development for athletes and sports enthusiasts, Altamira Therapeutics Ltd. has recently announced the successful testing of its Bentrio nasal spray, a preservative-free and drug-free solution for allergic rhinitis. This significant news, revealed on August 16, 2024, confirms that Bentrio is free from over 230 substances prohibited by the World Anti-Doping Agency (WADA), reinforcing its safety and suitability for competitive athletes.As many athletes know, managing allergies is crucial for peak performance, especially in outdoor sports where exposure to allergens is often unavoidable. Traditional medications for allergic rhinitis may contain substances that could lead to penalties or disqualif...
Altamira Therapeutics Announces Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis via Top Allergy Journal s Social Media ChannelsIn a recent announcement, Altamira Therapeutics Ltd. revealed the dissemination of positive results from the NASAR clinical trial with Bentrio nasal spray in seasonal allergic rhinitis (SAR) through the social media channels of Allergy, a leading journal in the field of allergology. This follows the previous publication of the peer-reviewed article AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial in the same journal.Altamira Therapeutics, a company focused on developing and commercializing RNA deli...
Altamira Therapeutics Ltd’s Comment on Sales, Marketing and Customers
The company operates within the biopharmaceutical industry, focusing on treatments for KRAS-driven cancers and rheumatoid arthritis (RA). In the KRAS-driven cancer segment, the market includes companies such as Amgen and Mirati Therapeutics, which have FDA-approved KRAS G12C inhibitors sotorasib and adagrasib for non-small cell lung cancer (NSCLC) with G12C-mutated KRAS. Additional companies developing treatments targeting single KRAS mutations include Genentech, Eli Lilly, Revolution Medicine, Boehringer Ingelheim, Silexion Therapeutics, and Nitto Denko. Treatments addressing multiple KRAS mutations are under development by Revolution Medicines, Boehringer Ingelheim, Eli Lilly, and Alterome Therapeutics.
In the rheumatoid arthritis market, competition involves large pharmaceutical companies marketing biologics targeting tumor necrosis factor-alpha (TNF-α), including adalimumab (AbbVie), infliximab (Johnson & Johnson), and etanercept (Amgen). Other biologics target B cells (rituximab, Roche), T cells (abatacept, Bristol-Myers Squibb), and interleukin-6 (tocilizumab, Genentech). Biosimilars have been introduced following patent expirations. Small molecule Janus kinase (JAK) inhibitors marketed by major companies include upadacitinib (AbbVie), tofacitinib (Pfizer), and baricitinib (Eli Lilly). Older therapies such as glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and disease-modifying antirheumatic drugs (DMARDs) also remain part of the RA treatment landscape.
Key customers and market participants identified include AbbVie, Alterome Therapeutics, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Genentech, Johnson & Johnson, Mirati Therapeutics, Nitto Denko, Pfizer, Revolution Medicine, Roche, and Silexion Therapeutics.
Sources:
Altamira Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Altamira Therapeutics Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Altamira Therapeutics Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
